Anastrozole

Generic Name
Anastrozole
Brand Names
Arimidex
Drug Type
Small Molecule
Chemical Formula
C17H19N5
CAS Number
120511-73-1
Unique Ingredient Identifier
2Z07MYW1AZ
Background

Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...

Indication

Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...

Associated Conditions
Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
Associated Therapies
-
cancernetwork.com
·

Early Breast Cancer Treatment Post the CDK4/6 Inhibitor Ribociclib's FDA Approval

Experts discussed the NATALEE trial and adjuvant ribociclib in breast cancer at an FDA Special Session, emphasizing the need for further studies on dosing and benefits. The trial included 5,101 patients, with 43% completing three years of adjuvant Kisqali. The FDA approved Kisqali in 2024 for HR-positive, HER2-negative early breast cancer, with postmarketing commitments for diversity and overall survival analyses.
curetoday.com
·

Looking Ahead After Kisqali's FDA Approval for Adjuvant Treatment of Early Breast Cancer

Kisqali, a CDK4/6 inhibitor, shows promise in treating HR-positive, HER2-negative early breast cancer, as demonstrated by the NATALEE trial. The trial involved 5,101 patients, with Kisqali given for three years alongside an aromatase inhibitor. Despite its FDA approval in 2024, follow-up studies are ongoing to assess additional benefits, dosing strategies, and overall survival. The trial highlighted the need for more diverse patient representation and ongoing research into optimal treatment durations and doses.
© Copyright 2024. All Rights Reserved by MedPath